Where I see patients (2)
My reviews
Selected research
-
A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.
Future oncology (London, England)
-
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma.
Cancer research
-
Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab.
Inflammatory bowel diseases
Clinical trials
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the ...
Recruiting
4.9